Analyst Price Targets — TRAW
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 3, 2025 11:09 am | Brandon Folkes | H.C. Wainwright | $8.00 | $2.35 | TheFly | Traws Pharma initiated with a Buy at H.C. Wainwright |
Latest News for TRAW
Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shot up 8.8% on Monday. The stock traded as high as $1.64 and last traded at $1.61. 21,635 shares were traded during trading, a decline of 60% from the average session volume of 54,220 shares. The stock had previously closed at $1.48. Wall Street Analysts Forecast
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID ® -ineligible patients, representing a significant population with no effective treatment options
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TRAW.
U.S. House Trading
No House trades found for TRAW.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.